8-K: INVO Fertility Reports 116% Revenue Growth in 2024, Focuses on Core Fertility Business

INVO Fertility announces strong 2024 financial results with significant revenue growth and improved Adjusted EBITDA, while also detailing a strategic shift to focus on its core fertility operations.

Summary

• INVO Fertility, Inc. announced its financial results for the fourth quarter and full year 2024.
• The company reported a 116% increase in revenue for 2024, reaching $6.532 million compared to $3.021 million in 2023.
• Consolidated clinic revenue increased by 125% to $6.450 million.
• Revenue from all clinics, including equity method clinics, increased by 78% to $7.731 million.
• The net loss increased to $(9.1) million due to the addition of NAYA Therapeutics and associated merger costs.
• Adjusted EBITDA improved to $(2.2) million compared to $(4.9) million in the previous year.
• In Q4 2024, revenue was $1.686 million, a 22% increase from $1.382 million in Q4 2023.
• Consolidated clinic revenue in Q4 2024 increased 24% to $1.687 million.
• The net loss for Q4 2024 increased to $(3.6) million due to the addition of NAYA Therapeutics and merger costs.
• Adjusted EBITDA for Q4 2024 was $(450,908), an improvement from $(1.0) million in the prior year.
• The company is divesting a majority stake in NAYA TX to refocus on its fertility business.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and improved EBITDA. The strategic decision to divest NAYA TX and focus on the core fertility business is also viewed favorably. However, the net losses temper the overall sentiment.

Positives

• The company achieved a 116% increase in revenue for 2024, reaching $6.5 million.
• Consolidated clinic revenue increased by 125% to $6.45 million.
• Adjusted EBITDA improved to $(2.2) million compared to $(4.9) million in the previous year.
• Adjusted EBITDA for the fourth quarter of 2024 was the best quarterly period in the company's recent history.
• The company is streamlining its operating structure to move towards positive cash flow.
• INVO Fertility is actively pursuing expansion into additional markets, leveraging the success of its existing fertility centers.
• The company is divesting a majority stake in NAYA TX to refocus on its core fertility operations.

Negatives

• The net loss increased to $(9.1) million for 2024 due to the addition of NAYA Therapeutics and associated merger costs.
• The net loss for Q4 2024 increased to $(3.6) million due to the addition of NAYA Therapeutics and merger costs.

Risks

• Forward-looking statements involve risks, uncertainties, and contingencies that may cause actual results to differ materially from anticipated results.
• The final separation from NAYA TX is subject to completing definitive transaction documents and key closing conditions, including receipt of necessary approvals.

Future Outlook

The company plans to continue capitalizing on favorable market trends and recent policy developments in fertility care, leveraging the success of its existing fertility centers and expanding into additional markets.

Management Comments

• 'We achieved record revenue during 2024 of $6.5 million, an increase of 116% compared to 2023, thanks to the hard work of our fertility teams at our clinics across the U.S.,' commented Steve Shum, CEO of INVO Fertility.
• Steve Shum also stated that the company has dramatically streamlined and improved its fertility-based operating structure to move the company towards positive cash flow.
• Steve Shum noted that the company is actively pursuing expansion into additional markets given the further declines in the U.S. fertility rate and rising public demand for solutions.

Industry Context

The global fertility services market is projected to grow due to rising infertility rates, delayed parenthood, and increasing acceptance of assisted reproductive technologies (ART). The company is positioning itself to capitalize on this growth by expanding access to care and focusing on its core fertility business.

Comparison to Industry Standards

• The Centers for Disease Control and Prevention reported a 50% increase in ART-conceived births from 2012 to 2021, with ART now accounting for 2.3% of all births, indicating a growing trend in the industry.
• INVO Fertility's focus on the IVC procedure using the INVOcell device aims to provide a more affordable alternative to traditional IVF, potentially capturing a larger segment of the market.

Stakeholder Impact

• Shareholders may benefit from the company's increased focus on its core fertility business and improved financial performance.
• Employees at the fertility clinics may benefit from the company's expansion plans.
• Patients may benefit from increased access to affordable fertility treatments.
• The divestiture of NAYA TX will allow that company to focus on its own opportunities and operations.

Next Steps

• Complete the divestiture of a majority stake in NAYA TX.
• Continue to streamline and improve the fertility-based operating structure.
• Actively pursue expansion into additional markets.
• Continue to engage in the sale and distribution of the INVOcell technology solution.

Key Dates

Keywords

fertility, INVO Fertility, IVF, revenue growth, Adjusted EBITDA, NAYA Therapeutics, divestiture, clinic expansion, ART, INVOcell